Literature DB >> 27367183

Current concepts of severe asthma.

Anuradha Ray, Mahesh Raundhal, Timothy B Oriss, Prabir Ray, Sally E Wenzel.   

Abstract

The term asthma encompasses a disease spectrum with mild to very severe disease phenotypes whose traditional common characteristic is reversible airflow limitation. Unlike milder disease, severe asthma is poorly controlled by the current standard of care. Ongoing studies using advanced molecular and immunological tools along with improved clinical classification show that severe asthma does not identify a specific patient phenotype, but rather includes patients with constant medical needs, whose pathobiologic and clinical characteristics vary widely. Accordingly, in recent clinical trials, therapies guided by specific patient characteristics have had better outcomes than previous therapies directed to any subject with a diagnosis of severe asthma. However, there are still significant gaps in our understanding of the full scope of this disease that hinder the development of effective treatments for all severe asthmatics. In this Review, we discuss our current state of knowledge regarding severe asthma, highlighting different molecular and immunological pathways that can be targeted for future therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27367183      PMCID: PMC4922699          DOI: 10.1172/JCI84144

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  117 in total

1.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

2.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Authors:  William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

3.  Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier.

Authors:  Helen M Lazear; Brian P Daniels; Amelia K Pinto; Albert C Huang; Sarah C Vick; Sean E Doyle; Michael Gale; Robyn S Klein; Michael S Diamond
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

4.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids.

Authors:  S E Wenzel; S J Szefler; D Y Leung; S I Sloan; M D Rex; R J Martin
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.

Authors:  Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes
Journal:  N Engl J Med       Date:  2014-05-20       Impact factor: 91.245

6.  Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3.

Authors:  D H Zhang; L Yang; L Cohn; L Parkyn; R Homer; P Ray; A Ray
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

7.  Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program.

Authors:  Kenneth Wysocki; Seo Young Park; Eugene Bleecker; William Busse; Mario Castro; Kian Fan Chung; Benjamin Gaston; Serpil Erzurum; Elliot Israel; W Gerald Teague; Charity G Moore; Sally Wenzel
Journal:  J Allergy Clin Immunol       Date:  2013-12-09       Impact factor: 10.793

8.  Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.

Authors:  R Pettipher; M G Hunter; C M Perkins; L P Collins; T Lewis; M Baillet; J Steiner; J Bell; M A Payton
Journal:  Allergy       Date:  2014-07-14       Impact factor: 13.146

9.  Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi.

Authors:  Victor E Barrios; Mark A Jarosinski; Clifford D Wright
Journal:  Biochem Pharmacol       Date:  2003-08-01       Impact factor: 5.858

10.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

View more
  81 in total

Review 1.  Contributions of the intestinal microbiome in lung immunity.

Authors:  Jeremy P McAleer; Jay K Kolls
Journal:  Eur J Immunol       Date:  2017-08-31       Impact factor: 5.532

2.  Do insights from mice imply that combined Th2 and Th17 therapies would benefit select severe asthma patients?

Authors:  Matthew E Poynter
Journal:  Ann Transl Med       Date:  2016-12

Review 3.  Updates on T helper type 17 immunity in respiratory disease.

Authors:  Naoki Iwanaga; Jay K Kolls
Journal:  Immunology       Date:  2018-10-24       Impact factor: 7.397

Review 4.  Interactive Roles of CaMKII/Ryanodine Receptor Signaling and Inflammation in Lung Diseases.

Authors:  Lan Wang; Roman G Ginnan; Yong-Xiao Wang; Yun-Min Zheng
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  The -Omic Approach to Understanding Glucocorticoid Effects in Smooth Muscle: Diving for Pearls.

Authors:  Rodney Britt; Y S Prakash
Journal:  Am J Respir Cell Mol Biol       Date:  2017-08       Impact factor: 6.914

6.  ALX receptor ligands define a biochemical endotype for severe asthma.

Authors:  Isabell Ricklefs; Ioanna Barkas; Melody G Duvall; Manuela Cernadas; Nicole L Grossman; Elliot Israel; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Loren C Denlinger; David T Mauger; Sally E Wenzel; Suzy A Comhair; Andrea M Coverstone; Merritt L Fajt; Annette T Hastie; Mats W Johansson; Michael C Peters; Brenda R Phillips; Bruce D Levy
Journal:  JCI Insight       Date:  2017-07-20

7.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

8.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

9.  A novel GABAA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo.

Authors:  Gene T Yocum; Jose F Perez-Zoghbi; Jennifer Danielsson; Aisha S Kuforiji; Yi Zhang; Guanguan Li; M S Rashid Roni; Revathi Kodali; Douglas C Stafford; Leggy A Arnold; James M Cook; Charles W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-29       Impact factor: 5.464

10.  Neutrophil cytoplasts induce TH17 differentiation and skew inflammation toward neutrophilia in severe asthma.

Authors:  Nandini Krishnamoorthy; David N Douda; Thayse R Brüggemann; Isabell Ricklefs; Melody G Duvall; Raja-Elie E Abdulnour; Kimberly Martinod; Luciana Tavares; Xiao Wang; Manuela Cernadas; Elliot Israel; David T Mauger; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; Benjamin M Gaston; Nizar N Jarjour; Sally Wenzel; Eleanor Dunican; John V Fahy; Daniel Irimia; Denisa D Wagner; Bruce D Levy
Journal:  Sci Immunol       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.